tbuckley/cabot-search huggingface dataset:
Bioinspired Polysaccharide‐Derived Zwitterionic Brush‐like Copolymer as an Injectable Biolubricant for Arthritis Treatment
Authors: Qinyu Yue, Lele Lei, Ya Gu, Ruijin Chen, Mingming Zhang, Haikuan Yu, Shang Li, Luming Yang, Yixin Zhang, Xiaoduo Zhao, Qiangbing Wei, Shuanhong Ma, Licheng Zhang, Peifu Tang, Feng Zhou
Journal: Advanced Healthcare Materials (2022)

Abstract Developing highly efficient and biocompatible biolubricants for arthritis treatment is extraordinarily demanded. Herein, inspired by the efficient lubrication of synovial joints, a paradigm that combines natural polysaccharide (chitosan) with zwitterionic poly[2‐(methacryloyloxy) ethyl phosphorylcholine] (PMPC), to design a series of brush‐like Chitosan‐ g ‐PMPC copolymers with highly efficient biological lubrication and good biocompatibility is presented. The Chitosan‐ g ‐PMPC copolymers are prepared via facile one‐step graft polymerization in aqueous medium without using any toxic catalysts and organic solvents. The as‐prepared Chitosan‐ g ‐PMPC copolymers exhibit very low coefficient of friction ( μ &lt; 0.01) on Ti 6 Al 4 V alloy substrate in both pure water and biological fluids. The superior lubrication is attributed primarily to the hydrated feature of PMPC side chains, interface adsorption of copolymer as well as to the hydrodynamic effect. In vivo experiments confirm that Chitosan‐ g ‐PMPC can alleviate the swelling symptom of arthritis and protect the bone and cartilage from destruction. Due to their facile preparation, distinctive lubrication properties, and good biocompatibility, Chitosan‐ g ‐PMPC copolymers represent a new type of biomimetic lubricants derived from natural biopolymer for promising arthritis treatment and artificial joint lubrication.
The pelvitrainer for training in laparoscopic surgery – A prospective, multicenter, interdisciplinary study: Experimental research
Authors: Johannes Ackermann, Julia Pahls, Jorun Baumann, Carolin Spüntrup, Bernd Holthaus, Günter Noé, Michael Anapolski, Ivo Meinhold-Heerlein, Antonio Simone Laganà, Göntje Peters, Julian Pape, Damaris Willer, Anna Maria Westermann, Veronika Günther, Nicolai Maass, Liselotte Mettler, Ibrahim Alkatout
Journal: International Journal of Surgery (2022)
Calculated versus measured albumin-creatinine ratio to predict kidney failure and death in people with chronic kidney disease
Authors: Huda Al-Wahsh, Ngan N. Lam, Robert R. Quinn, Paul E. Ronksley, Manish M. Sood, Brenda Hemmelgarn, Navdeep Tangri, Thomas Ferguson, Marcello Tonelli, Pietro Ravani, Ping Liu
Journal: Kidney International (2022)
Patterns in Transvaginal Mesh Surgery After Government Regulation in the United States
Authors: Patrick Lewicki, Aaron Brant, Spyridon P. Basourakos, Yuqing Qiu, Bilal Chughtai, Jonathan E. Shoag
Journal: JAMA Surgery (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue
TCTAP C-108 Septal Artery Perforation During Wire Advancement for Percutaneous Coronary Intervention of Proximal Left Anterior Descending Artery Calcified Lesion - How We Persevere Till the End
Authors: Choon Keong Tee, Mahadevan Gurudevan, Heng Shee Kim, Vicknesan Kulasingham, Adelyn H, Kumutha Gobal, Surenthiran Ramanathan, Kamaraj Selvaraj
Journal: Journal of the American College of Cardiology (2022)
Implications for School Practices of the Association of Child Bereavement With School Grades
Authors: Irwin Sandler
Journal: JAMA Network Open (2022)

healthy development.Schools naturally need to address issues such as how to welcome the child back to the classroom after the death, how to inform classmates about the death, and how the teacher can support the child and deal with changes in bereaved children's schoolwork or behavior in the classroom.Liu et al 1 make the reasonable suggestion that schools may be helpful by providing additional educational support and by supporting the bereaved caregiver.There is increasing public awareness of the need to support bereaved children because of the many children who have experienced the death of a parent or caregivers due to the COVID-19 pandemic.Evidence of growing efforts to help schools support bereaved children can be seen in a recent initiative by the New York Life Foundation to support grief-sensitive schools. 6The growing awareness of the need to support bereaved children makes this a propitious time to consider what else schools might do to promote the healthy development, as well as academic success, of these children.In addition to what they do in the classroom, schools can also be a link to evidence-based programs that bereaved families can access either in their community or online.There is increasing evidence for the efficacy of some programs to promote the resilience of bereaved children, by supporting either effective coping or the caregiver's ability to support their grieving children. 7As the institution that has direct contact with almost all bereaved children, schools can play a critical role in promoting the academic success, as well as healthy development, of bereaved children by becoming educated as to the evidence-based programs that are available in their community and helping bereaved families access these resources.
Deadenylase-dependent mRNA decay of GDF15 and FGF21 orchestrates food intake and energy expenditure
Authors: Sakie Katsumura, Nadeem Siddiqui, Michael Rock Goldsmith, Jaime H Cheah, Teppei Fujikawa, Genki Minegishi, Atsushi Yamagata, Yukako Yabuki, Kaoru Kobayashi, Mikako Shirouzu, Takeshi Inagaki, Tim H-M Huang, Nicolas Musi, Ivan Topisirovic, Ola Larsson, Masahiro Morita
Journal: Cell Metabolism (2022)
TCTAP A-018 Safety, Feasibility, and Compatibility of Percutaneous Coronary Intervention (PCI) via Distal Radial Approach (dRA) in Daily Practice
Authors: Hironobu Kikuchi, Tatsuya Kamon, Kazutoshi Hirose, Hiroki Shinohara, Hiroyuki Kiriyama, Akihito Saito, Mizuki Miura, Shun Minatsuki, Satoshi Kodera, Jiro Ando, Norifumi Takeda, Issei Komuro
Journal: Journal of the American College of Cardiology (2022)
Metabolic obesity phenotypes: a friend or foe of digestive polyps?—An observational study based on National Inpatient Database
Authors: Yiping Cheng, Junming Han, Qihang Li, Yingzhou Shi, Fang Zhong, Yafei Wu, Zhixiang Wang, Zhongshang Yuan, Xiude Fan, Jiajun Zhao
Journal: Metabolism (2022)
TCTAP C-167 Percutaneous Transcatheter Closure of Large Spontaneous Ruptured Sinus of Valsalva Aneurysm in a Young Female Patient Using the Amplatzer Duct Occluder
Authors: Krunal Krishnakant Tamakuwala, Abhishek Rajpopat, Vivek Nanda
Journal: Journal of the American College of Cardiology (2022)
Hypersensitive or hypertensive? IgE–FcɛR1 signalling in mast cells adds a new piece to the immunity and hypertension puzzle
Authors: Lale A Ertuglu, Annet Kirabo
Journal: Cardiovascular Research (2022)

Journal Article Accepted manuscript Hypersensitive or hypertensive? IgE-FcεR1 signaling in mast cells adds a new piece to the immunity and hypertension puzzle Get access Lale A. Ertuglu, Lale A. Ertuglu Division of Nephrology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA Search for other works by this author on: Oxford Academic PubMed Google Scholar Annet Kirabo Annet Kirabo Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA Address for correspondence: Annet Kirabo, DVM, MSc, PhD, FAHA Vanderbilt University Medical Center Room 536 Robinson Research Building Nashville, TN 37232-6602 e-mail: Annet.Kirabo@vumc.org Search for other works by this author on: Oxford Academic PubMed Google Scholar Cardiovascular Research, cvac028, https://doi.org/10.1093/cvr/cvac028 Published: 14 April 2022 Article history Received: 28 January 2022 Revision received: 24 February 2022 Accepted: 01 March 2022 Published: 14 April 2022
TCTAP A-037 Prognostic Impact of CHA2DS2-VASc-HS Score on Midterm Clinical Outcomes After Elective PCI for Chronic Coronary Syndrome: A Single-Center Retrospective Study
Authors: Tomoaki Ukaji, Tetsuya Ishikawa, Kota Yamada, Yukiko Mizutani, Hidehiko Nakamura, Itaru Hisauchi, Yuji Itabashi, Shiro Nakahara, Sayuki Kobayashi, Isao Taguchi
Journal: Journal of the American College of Cardiology (2022)
Assessment of hyperprogression versus the natural course of disease development with nivolumab with or without ipilimumab versus placebo in phase III, randomized, controlled trials
Authors: Yoon-Koo Kang, Martin Reck, Paul Nghiem, Yan Feng, Gregory Plautz, Hye Ryun Kim, Taofeek K Owonikoko, Narikazu Boku, Li-Tzong Chen, Ming Lei, Han Chang, Wen Hong Lin, Amit Roy, Akintunde Bello, Jennifer Sheng
Journal: Journal for ImmunoTherapy of Cancer (2022)

Background Retrospective studies have suggested a potential risk of hyperprogressive disease (HPD) in patients receiving immune checkpoint inhibitors (ICIs). We compared the incidence of HPD during treatment with nivolumab±ipilimumab versus natural tumor progression with placebo in post hoc analyses of two randomized, double-blind clinical trials. Methods ATTRACTION-2 randomized patients with advanced gastric or gastroesophageal junction cancer (GC/GEJC) and progression on ≥2 prior regimens to nivolumab 3 mg/kg Q2W or placebo. CheckMate 451 randomized patients with extensive-disease small cell lung cancer (ED SCLC) and ongoing complete/partial response or stable disease after first-line chemotherapy to nivolumab 240 mg Q2W, nivolumab 1 mg/kg+ipilimumab 3 mg/kg Q3W for four doses then nivolumab 240 mg Q2W, or placebo. Patients receiving ≥1 dose of study drug and with tumor scans at baseline and the first on-treatment evaluation were included in the HPD analyses. HPD definitions were ≥20%, ≥50%, and ≥100% increase in target lesion sum of the longest diameters (SLD) at the first on-treatment assessment. Results In the ATTRACTION-2 HPD-evaluable population, 243 patients received nivolumab and 115 placebo. Fewer patients receiving nivolumab versus placebo had increases in SLD ≥20% (33.7% vs 46.1%) and ≥50% (6.2% vs 11.3%); similar proportions had increases in SLD ≥100% (1.6% vs 1.7%). In the CheckMate 451 HPD-evaluable population, 177 patients received nivolumab, 179 nivolumab+ipilimumab, and 175 placebo. Fewer patients receiving nivolumab or nivolumab+ipilimumab versus placebo had increases in SLD ≥20% (27.1%, 27.4% vs 45.7%), ≥50% (10.2%, 11.2% vs 22.3%), and ≥100% (2.8%, 2.8% vs 6.3%). Conclusions Nivolumab±ipilimumab was not associated with an increased rate of progression versus placebo in patients with GC, GEJC, or ED SCLC, suggesting that previous reports of HPD may reflect the natural disease course in some patients rather than ICI-mediated progression. Trial registration number NCT02538666 ; NCT02267343 .
Enhancement of blood–brain barrier penetration and the neuroprotective effect of resveratrol
Authors: Nikita Katila, Ramesh Duwa, Sunil Bhurtel, Shristi Khanal, Srijan Maharjan, Jee-Heon Jeong, Sooyeun Lee, Dong-Young Choi, Simmyung Yook
Journal: Journal of Controlled Release (2022)
Expanded COVID-19 phenotype definitions reveal distinct patterns of genetic association and protective effects
Authors: Genevieve H. L. Roberts, Raghavendran Partha, Brooke Rhead, Spencer C. Knight, Danny S. Park, Marie V. Coignet, Miao Zhang, Nathan Berkowitz, David A. Turrisini, Michael Gaddis, Shannon R. McCurdy, Milos Pavlovic, Luong Ruiz, Chodon Sass, Asher K. Haug Baltzell, Harendra Guturu, Ahna R. Girshick, Catherine A. Ball, Eurie L. Hong, Kristin A. Rand
Journal: Nature Genetics (2022)
Oral tyrosine kinase 2 inhibitor PF-06826647 demonstrates efficacy and an acceptable safety profile in participants with moderate-to-severe plaque psoriasis in a phase 2b, randomized, double-blind, placebo-controlled study
Authors: Christopher Tehlirian, Ravi Shankar P. Singh, Vivek Pradhan, Erika S. Roberts, Sanela Tarabar, Elena Peeva, Michael S. Vincent, Jeremy D. Gale
Journal: Journal of the American Academy of Dermatology (2022)

Psoriasis treatments lack durable efficacy and have inconvenient administration, highlighting the need for new therapies.To evaluate the efficacy and safety of tyrosine kinase 2 inhibitor, PF-06826647, in moderate-to-severe plaque psoriasis.This phase 2b, double-blind study randomized participants to oral, once-daily PF-06826647 (1:1:2:2:2) 50:100:200:400 mg:placebo (16 weeks), then 200 or 400 mg (24 weeks) (NCT03895372). The primary end point was a proportion of participants achieving psoriasis area severity index (PASI) 90 at week 16. Secondary end points (PASI50/75/90/100; Physician's Global Assessment) and safety were assessed to week 40.Overall, 178 participants were treated. A significantly greater proportion of participants (risk difference % [90% CI]) achieved PASI90 in the 200-mg (33.0 [18.0, 47.1], P = .0004) and 400-mg (46.5 [30.6, 60.6], P < .0001; week 16) groups versus placebo. Significant increases from placebo were observed for all secondary end points (200 and 400 mg; weeks 6-16; P < .05); increases were evident to week 40 (categorical data). PF-06826647 was well tolerated and most treatment-emergent adverse events were mild/moderate. Eighteen participants discontinued due to treatment-emergent adverse events (14 arising from laboratory abnormalities).Limitations included the large proportion of White males and non-placebo-controlled extension.PF-06826647 200 and 400 mg once daily showed significant efficacy versus placebo at week 16 and was well tolerated over 40 weeks.
The programmed site-specific delivery of LY3200882 and PD-L1 siRNA boosts immunotherapy for triple-negative breast cancer by remodeling tumor microenvironment
Authors: Pan Zhang, Chao Qin, Nan Liu, Xinyuan Zhou, Xuxin Chu, Fangnan Lv, Yongwei Gu, Lifang Yin, Jiyong Liu, Jianping Zhou, Meirong Huo
Journal: Biomaterials (2022)
TCTAP C-011 ST-Elevation STEMI With High Thrombus Burden
Authors: Vicknesan Kulasingham, Gurudevan Mahadevan, Tee Choon Keong, Heng Shee Kim, Adelyn Nisha Henry, Kumutha Gobal, Azrina Abdul Kadir, Kim Fong Ng
Journal: Journal of the American College of Cardiology (2022)
<i>Notes from the Field</i>: Enteropathogenic <i>Escherichia coli</i> Outbreak at a Child Care Center — Oregon, August 2021
Authors: Kimberly E. Bonner, McKenna Carter, Christopher Zielinski, Karim Morey, Lillian McLitus, Emilio DeBess, Julie Hatch, Richard Leman
Journal: MMWR Morbidity and Mortality Weekly Report (2022)
TCTAP A-015 Acute and Mid-Term Results of Percutaneous Coronary Intervention for Severely Calcified Coronary Artery Lesions With Orbital Atherectomy System (OAS)
Authors: Jumpei Koike, Yoshihiro Iwasaki, Atsushi Funatsu, Tomoko Kobayashi, Shigeru Nakamura
Journal: Journal of the American College of Cardiology (2022)
Beneficial effect of ursodeoxycholic acid in patients with acyl‐CoA oxidase 2 (ACOX2) deficiency–associated hypertransaminasemia
Authors: Marta Alonso‐Peña, Ricardo Espinosa‐Escudero, Elisa Herraez, Oscar Briz, Maria Luisa Cagigal, Jesus M. Gonzalez‐Santiago, Aida Ortega‐Alonso, Conrado Fernandez‐Rodriguez, Luis Bujanda, Marta Calvo Sanchez, Delia D´Avola, Maria‐Carlota Londoño, Moises Diago, Jose C. Fernandez‐Checa, Carmen Garcia‐Ruiz, Raul J. Andrade, Frank Lammert, Jesus Prieto, Javier Crespo, Javier Juamperez, Alvaro Diaz‐Gonzalez, Maria J. Monte, Jose J. G. Marin
Journal: Hepatology (2022)

Abstract Background and Aims A variant (p.Arg225Trp) of peroxisomal acyl‐CoA oxidase 2 (ACOX2), involved in bile acid (BA) side‐chain shortening, has been associated with unexplained persistent hypertransaminasemia and accumulation of C27‐BAs, mainly 3α,7α,12α‐trihydroxy‐5β‐cholestanoic acid (THCA). We aimed to investigate the prevalence of ACOX2 deficiency‐associated hypertransaminasemia (ADAH), its response to ursodeoxycholic acid (UDCA), elucidate its pathophysiological mechanism and identify other inborn errors that could cause this alteration. Methods and Results Among 33 patients with unexplained hypertransaminasemia from 11 hospitals and 13 of their relatives, seven individuals with abnormally high C27‐BA levels (&gt;50% of total BAs) were identified by high‐performance liquid chromatography‐mass spectrometry. The p.Arg225Trp variant was found in homozygosity (exon amplification/sequencing) in two patients and three family members. Two additional nonrelated patients were heterozygous carriers of different alleles: c.673C&gt;T (p.Arg225Trp) and c.456_459del (p.Thr154fs). In patients with ADAH, impaired liver expression of ACOX2, but not ACOX3, was found (immunohistochemistry). Treatment with UDCA normalized aminotransferase levels. Incubation of HuH‐7 hepatoma cells with THCA, which was efficiently taken up, but not through BA transporters, increased reactive oxygen species production (flow cytometry), endoplasmic reticulum stress biomarkers ( GRP78 , CHOP , and XBP1‐S/XBP1‐U ratio), and BAXα expression (reverse transcription followed by quantitative polymerase chain reaction and immunoblot), whereas cell viability was decreased (tetrazolium salt‐based cell viability test). THCA‐induced cell toxicity was higher than that of major C24‐BAs and was not prevented by UDCA. Fourteen predicted ACOX2 variants were generated (site‐directed mutagenesis) and expressed in HuH‐7 cells. Functional tests to determine their ability to metabolize THCA identified six with the potential to cause ADAH. Conclusions Dysfunctional ACOX2 has been found in several patients with unexplained hypertransaminasemia. This condition can be accurately identified by a noninvasive diagnostic strategy based on plasma BA profiling and ACOX2 sequencing. Moreover, UDCA treatment can efficiently attenuate liver damage in these patients.
Efficacy and Safety of AbobotulinumtoxinA in Patients with Neurogenic Detrusor Overactivity Incontinence Performing Regular Clean Intermittent Catheterization: Pooled Results from Two Phase 3 Randomized Studies (CONTENT1 and CONTENT2)
Authors: Michael Kennelly, Francisco Cruz, Sender Herschorn, Paul Abrams, Kadir Onem, Viktor Kibanov Solomonov, Elena del Rosario Figueroa Coz, Andrei Manu-Marin, Antonella Giannantoni, Catherine Thompson, Claire Vilain, Magali Volteau, Pierre Denys
Journal: European Urology (2022)

For patients with neurogenic detrusor overactivity incontinence (NDOI), treatment with oral medications is often unsatisfactory. To assess the efficacy and safety of abobotulinumtoxinA (aboBoNT-A) for NDOI. Two randomized, double-blind phase 3 studies (CONTENT1, NCT02660138; CONTENT2, NCT02660359) enrolled patients with NDOI who were regularly performing clean intermittent catheterization (CIC) and were inadequately managed with oral therapy. Pooled results from the first placebo-controlled treatment cycle are reported. Patients received injections of aboBoNT-A 600 U (n = 162) or 800 U (n = 161) or placebo (n = 162) into the detrusor muscle. The primary endpoint was the mean change from baseline in NDOI episodes per week at week 6. Secondary endpoints reported are the proportion of patients with no NDOI episodes, the volume per void, urodynamic parameters, and quality of life (QoL). Safety was also assessed. Statistical analyses were conducted for the pooled study populations (each aboBoNT-A dose vs placebo). At week 6, NDOI episodes per week were significantly reduced in each aboBoNT-A group versus placebo (both p < 0.001) and the volume per void had significantly increased. Approximately one-third of patients in each aboBoNT-A dose group reported no NDOI episodes versus 3% of patients in the placebo group. Reductions in urinary incontinence (UI) were reflected in significantly greater improvements in UI-related QoL in the aboBoNT-A groups versus placebo. Urodynamic parameters (bladder capacity and detrusor pressure) were significantly improved with each aboBoNT-A dose versus placebo. Each aboBoNT-A dose was well tolerated. Symptomatic urinary tract infection was the most frequent treatment-emergent adverse event, with incidence comparable across the aboBoNT-A and placebo groups. The studies were terminated prematurely owing to slow recruitment and were not designed for statistical comparison between the two aboBoNT-A doses. Intradetrusor aboBoNT-A is an effective treatment and alternative option for patients with NDOI who have an inadequate response to oral anticholinergics and are already performing CIC. In patients with bladder muscle overactivity caused by neurological conditions (multiple sclerosis or spinal cord injury) and resulting in urinary incontinence, abobotulinumtoxinA injections improved their symptoms and bladder function, with no unexpected effects.
Annals Graphic Medicine - No Access: Barriers for People With Disabilities
Authors: Sujal Manohar
Journal: Annals of Internal Medicine (2022)

Web ExclusivesMarch 2022Annals Graphic Medicine - No Access: Barriers for People With DisabilitiesFREESujal Manohar, BS, BASujal Manohar, BS, BABaylor College of Medicine, Houston, Texas (S.M.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/G21-0039 SectionsAboutVisual AbstractPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Download figure Download PowerPoint Comments0 CommentsSign In to Submit A Comment Cara Foldes MD, MPHBaylor College of Medicine8 March 2022 Thank you Beautiful and thought provoking! Disclosures: Baylor College of Medicine Author, Article, and Disclosure InformationAffiliations: Baylor College of Medicine, Houston, Texas (S.M.)Disclosures: The author has reported no disclosures of interest. The form can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=G21-0039.Author/Illustrator Information: Sujal Manohar, BS, BA, is a first-year medical student at Baylor College of Medicine (e-mail, sujal.[email protected]edu). Her creative work can be viewed at sujalmanohar.com.This article was published at Annals.org on 8 March 2022. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics March 2022Volume 175, Issue 3Page: W29-W30 ePublished: 8 March 2022 Issue Published: March 2022 Copyright & PermissionsCopyright © 2022 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
TCTAP A-069 Cost-Effectiveness Analysis of High-Potency Versus Low-Potency Statins for Reducing Mortality in Coronary Artery Disease Patients on Dual Antiplatelet Therapy Post Percutaneous Coronary Intervention.
Authors: Shaban Mohammed, Abdul Rahman Arabi, Dina Abushanab, Sawsan Almukdad, Rania Abdel-Latif, Ayman El-Menyar, Salah Arafa, Ihsan Rafie, Awad Alqahtani, Moza Al Hail, Nidal Asaad, Jassim Al Suwaidi
Journal: Journal of the American College of Cardiology (2022)
External Validation of the FREEDOM Score for Individualized Decision Making Between CABG and PCI
Authors: Kuniaki Takahashi, Patrick W. Serruys, Valentin Fuster, Michael E. Farkouh, John A. Spertus, David J. Cohen, Seung-Jung Park, Duk-Woo Park, Jung-Min Ahn, Yoshinobu Onuma, David M. Kent, Ewout W. Steyerberg, David van Klaveren
Journal: Journal of the American College of Cardiology (2022)